Table 2 Distribution of demographic and clinical variables from a subset of patients who underwent targeted sequencing (n = 23)

From: Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma

 

Number (%)

Gender:

Male

17 (74)

Median age (years, range)

67 (50–86)

Cirrhosis

21 (91)

Aetiology:

HBV

1 (4)

HCV

9 (39)

Alcohol

5 (22)

NASH

7 (30)

Other

1 (4)

BCLC stage:

A

5 (22)

B

15 (65)

C

1 (4)

Child-Pugh class:

A

22 (96)

B

1 (4)

Median tumour size (cm, range)

3.5 (1.2–14)

AFP, median (ng/mL) (range)

7.5 (1.9–803)

  1. HBV Hepatitis B virus, HCV Hepatitis C virus, NASH Non-alcoholic steatohepatitis, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer score.
Back to article page